Sam Brusco, Associate Editor10.09.23
Hyperfine has gained U.S. Food and Drug Administration (FDA) clearance for updated, artificial intelligence (AI)-powered software that aims to enhance image quality for the Swoop portable MR brain imaging system’s diffusion-weighted imaging (DWI) sequence).
The software update, according to the company, will expand Swoop’s AI denoising capabilities by incorporating image post-processing into the DWI sequence. Hyperfine said the system’s other sequences—T1, T2, and FLAIR—previously benefitted from the AI feature.
Denoising provides a crisper image to potentially help clinicians more accurately diagnose, treat, and monitor patients receiving brain imaging.
We believe in making brain imaging more accessible, clinically relevant, and actionable. We continue to make meaningful progress across all sequences. With this significant and most recent update, we now incorporate deep learning into our DWI sequence,” Hyperfine’s COO Tom Teisseyre told the press. “These imaging improvements will serve a critical role in enhancing image quality for healthcare professionals in time-sensitive environments.”
Hyperfine’s president and CEO Maria Sainz added, “Our eighth FDA software clearance in three years for the Swoop system underscores our relentless drive for innovation and continuous improvement. Our focus remains on providing quality brain imaging to more providers and patients in more sites of care. More than milestones, it's about reshaping patient care, empowering clinicians, and advancing brain imaging.”
The company said it plans to roll out the updated software in the months to come.
The software update, according to the company, will expand Swoop’s AI denoising capabilities by incorporating image post-processing into the DWI sequence. Hyperfine said the system’s other sequences—T1, T2, and FLAIR—previously benefitted from the AI feature.
Denoising provides a crisper image to potentially help clinicians more accurately diagnose, treat, and monitor patients receiving brain imaging.
We believe in making brain imaging more accessible, clinically relevant, and actionable. We continue to make meaningful progress across all sequences. With this significant and most recent update, we now incorporate deep learning into our DWI sequence,” Hyperfine’s COO Tom Teisseyre told the press. “These imaging improvements will serve a critical role in enhancing image quality for healthcare professionals in time-sensitive environments.”
Hyperfine’s president and CEO Maria Sainz added, “Our eighth FDA software clearance in three years for the Swoop system underscores our relentless drive for innovation and continuous improvement. Our focus remains on providing quality brain imaging to more providers and patients in more sites of care. More than milestones, it's about reshaping patient care, empowering clinicians, and advancing brain imaging.”
The company said it plans to roll out the updated software in the months to come.